Anne Altmeyer - 10 Jun 2026 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Reporting relationship: Director
Issuer ticker: CRBP
Reported as of: 10 Jun 2026
Net transaction value: -$19,088
SEC form: 4
Accepted by SEC: 11 Jun 2026, 16:30:12 UTC
Prior SEC filing: 21 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Meghan Houghton, attorney-in-fact for Anne Altmeyer

Key filing fact

Anne Altmeyer filed Form 4 for Corbus Pharmaceuticals Holdings, Inc. (CRBP) on 11 Jun 2026.

Key facts

This page summarizes Anne Altmeyer's Form 4 filing for Corbus Pharmaceuticals Holdings, Inc. (CRBP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 21 May 2026.
Current net transaction value: -$19,088.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001947086 Primary reporting owner

Altmeyer Anne

Relationship: Director
Address: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD
Signature: /s/ Meghan Houghton, attorney-in-fact for Anne Altmeyer
Signature date: 11 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRBP transaction

Common Stock, par value $0.0001 per share

Sale

Transaction value: $19,088
Shares: -2,412
Change %: -24%
Price: $7.91
Shares after: 7,579
Date: 10 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.

Footnote F2

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.